Lung Cancer Clinical Trials

Showing 421-440 of 4,288 trials

A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC

NCT04900363

This trial is a Phase Ib/II study. All patients are stage IIIB/C or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 in subjects with advanced NSCLC whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%.

Non-small Cell Lung Cancer

Akeso108 participantsStarted May 2021

Shanghai, Shanghai Municipality, China

RECRUITINGPhase 1

A Study of LY4175408 in Participants With Advanced Cancer

NCT07046923

The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.

Carcinoma, Non-Small-Cell LungSmall Cell Lung CarcinomaEndometrial Neoplasms+2 more

Eli Lilly and Company240 participantsStarted Jul 2025

Stanford, California, United States • Orlando, Florida, United States • Sarasota, Florida, United States +21 more locations

A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC

A Study of LY4175408 in Participants With Advanced Cancer

Related Searches

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

Study of Three Endpoints to Assess the Benefit of Rehabilitation in Patients With Advanced Non-small Cell Lung Cancer Controlled After at Least 6 Months of Systemic Treatment

A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

FDG PET/CT in Lung Cancer Staging

Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)